- Home
- MCAH vs ACRV Comparison
MCAH vs ACRV Comparison
Compare MCAH & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCAH | ACRV |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.1M | 74.0M |
| IPO Year | 2026 | 2022 |
Fundamental Metrics
Financial Performance| Metric | MCAH | ACRV |
|---|---|---|
| Price | $9.98 | $1.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 21.2K | ★ 285.9K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $568.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.92 | $1.27 |
| 52 Week High | $9.97 | $3.56 |
Technical Indicators
Market Signals| Indicator | MCAH | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 67.55 | 61.71 |
| Support Level | $9.95 | $1.78 |
| Resistance Level | N/A | $1.86 |
| Average True Range (ATR) | 0.00 | 0.09 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 100.00 | 94.62 |
Price Performance
Historical ComparisonAbout MCAH Mountain Crest Acquisition 6 Corp. Ordinary Shares
Mountain Crest Acquisition 6 Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.